PATENT CLAIM ANALYSIS

Application Number: 15949703
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["514", "225200"]

Abstract:
The subject invention concerns materials and methods for treating depression, stress disorders, such as PTSD, anxiety disorders, and/or a neurodegenerative disease or condition in a person or animal. In one embodiment, a person or animal in need of treatment is administered one or more compounds or drugs, or a composition comprising the one or more compounds or drugs, that inhibit FKBP51 activity or function. The subject invention also concerns a method for inhibiting activity of the FKBP51 protein in a cell. The subject invention also concerns methods of screening for compounds or drugs that inhibit the FKBP51 protein.

Claim (Index 12):
The method according to  claim 1 , wherein the compound or drug is benztropine, clonidine, pimozide, thioridazine, trifluoperazine, or triflupromazine, or a pharmaceutically or physiologically acceptable salt thereof.

Metadata:
- Claim Count in Document: 27.0
- Percentile: 91.0
- Lexical Diversity: 2.09615
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15209594', '14788364', '12994560', '15467867', '15655683']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7327429267766472
- 35 USC 102 Novelty (BERT): 0.5474274739008815
- Combined Prediction Score: 0.7142113814890706
- Mean Citation Score: 238.789368
- Max Citation Score: 377.39816
- Similarity Product: 374.7042642161513

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test